| Description |
DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance[1].
|
| Related Catalog |
|
| Target |
HIV
|
| In Vitro |
DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase[1].
|
| In Vivo |
DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg[1]. DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values[1]. Animal Model: Wistar rats[1] Dosage: Tail vein injection Administration: 20 mg/kg Result: Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg. Animal Model: Rats[1] Dosage: I.v. bolus injection (Pharmacokinetic Analysis) Administration: 10 mg/kg; 0~25 hours Result: Rapidly eliminated the half-life elimination and the plasmatic clearance values.
|
| References |
[1]. Brai A, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci U S A. 2016;113(19):5388-5393.
|
